Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Ruth Aranda et al.|Clinical Cancer Research|2017Cited by 147
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, David Berz et al.|Journal of Thoracic Oncology|2023Cited by 38
Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancerMark M. Awad, Andrew J. Aguirre, Shengwu Liu et al.|Cancer Research|2021Cited by 12
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0